Drugs / 4SCAR7U
4SCAR7U
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05995028 | Oct 2023 → Sep 2026 overdue | T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma, acute myeloid leukemia | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4SCAR7U | “The 4SCAR7U T cells are genetically engineered and manufactured in bulk amount that can be supplied off-the-shelf without being custom made from individual patients.” NCT05995028 ↗ |
| Known as | 4SCAR7U T cells | “Infusion of 4SCAR7U T cells” NCT05995028 ↗ |
| Known as | Universal 4SCAR7U cells | “Universal 4SCAR7U cells to treat CD7-positive hematological malignancies” NCT05995028 ↗ |
| Modality | Cell therapy | “The 4SCAR7U T cells are genetically engineered” NCT05995028 ↗ |